Legionnaires' Disease

Legionnaires' disease is an atypical pneumonia caused by Legionella pneumophila (and other Legionella species), acquired through inhalation of aerosolized contaminated water. It accounts for ~5% of all-cause CAP but is one of the three most common causes of CAP requiring ICU admission, with mortality ranging from 4% to 40% depending on host factors and treatment timing. [1] It is a notifiable disease in most jurisdictions.

• Exposure history is critical: Ask about hotel/resort stays, cruise ships, hot tubs/spas, cooling towers, hospital water systems, decorative fountains — all within the prior 2–14 days (incubation period) [2-3]
• Prodrome: Headache, myalgia, asthenia, anorexia preceding respiratory symptoms
• Symptom characterization: High fever (often >40°C), initially dry cough progressing to mildly productive, dyspnea, pleuritic chest pain [3]
• GI symptoms are a hallmark: Watery (non-bloody) diarrhea (19–47%), nausea/vomiting (9–25%), abdominal pain [3-4]
• Neurological symptoms: Headache, confusion, obtundation — present in 38–53% [3]
• Important negatives: Lack of response to prior β-lactam therapy should raise suspicion [2][5]

• Rapidly progressive multilobar infiltrates despite antibiotics
• Respiratory failure / need for mechanical ventilation
• Hemodynamic instability / septic shock
• Altered mental status, seizures, focal neurological deficits
• Rhabdomyolysis with acute renal failure [2]
• Cavitation on imaging (especially in immunosuppressed patients) [3]
• ICU admission required in nearly one-third of cases [1]

• First-line treatment: Azithromycin 500 mg daily or Levofloxacin 750 mg daily [2-3]
• Doxycycline is an acceptable alternative [3]
• β-lactams and aminoglycosides are ineffective — Legionella is an obligate intracellular pathogen [2-3]
• No evidence supports combination therapy (macrolide + fluoroquinolone) over monotherapy, even in severe disease [2][6]
• Duration: Levofloxacin 5–10 days; azithromycin 3–5 days (standard) up to 10 days (severe/immunocompromised); other agents 10–14 days, extended to 21 days in immunocompromised patients [2-3]
• Transplant patients: Avoid older macrolides (erythromycin, clarithromycin) due to CYP450 interactions with tacrolimus/cyclosporine — use fluoroquinolones, doxycycline, or azithromycin instead [3-4]
• Parenteral therapy until clinical response, then step down to oral [3-4]

• Maintain adequate hydration, especially with high fevers and diarrhea
• NPO considerations if altered mental status or impending intubation
• No specific dietary triggers or long-term dietary management

• Pulmonary: Cough (41–92%), dyspnea (36–56%), pleuritic chest pain (14–50%)
• GI: Diarrhea, nausea/vomiting, abdominal pain — prominence of GI symptoms in a pneumonia patient is a classic clue [3][5]
• Neurological: Confusion, headache, obtundation, seizures [3]
• Musculoskeletal: Myalgia/arthralgia (20–43%), rhabdomyolysis
• Renal: Oliguria, dark urine (myoglobinuria), microscopic hematuria [3]
• Cardiac: Chest pain — rare myocarditis, pericarditis [4]

• Collateral: Determine if other individuals from the same hotel, workplace, hospital, or building are ill — cluster identification is essential for public health response [2]
• Detailed travel history within the past 10–14 days
• Occupational exposures (plumbing, HVAC maintenance, construction near water systems)
• No hereditary predisposition; family history is generally not contributory
• Social context: Smoking and alcohol use history are important risk modifiers [2]

• Smoking (strongest modifiable risk factor)
• Chronic lung disease (COPD, emphysema)
• Immunosuppression: Organ transplant recipients, corticosteroid use, hematologic malignancies, HIV/AIDS [1-2]
• Diabetes mellitus
• Chronic cardiovascular disease
• Alcohol misuse
• Age >50 years, male sex [2][5]
• Environmental: Exposure to contaminated water systems — hospitals, hotels, cooling towers, hot tubs
• Seasonal: Peak incidence late spring through early autumn (June–October in the Northern Hemisphere) [7]

• Streptococcus pneumoniae pneumonia — most common CAP; less likely to have prominent GI/neuro symptoms
• Mycoplasma pneumoniae — younger patients, milder course, more upper respiratory symptoms
• Chlamydia psittaci — bird exposure; similar atypical presentation but less severe cough [8]
• Influenza / COVID-19 pneumonia — viral prodrome, myalgias; test with NAAT
• Pulmonary embolism — pleuritic chest pain + hemoptysis can mimic; consider if risk factors present [4]
• Q fever (Coxiella burnetii) — animal exposure, hepatitis, atypical pneumonia
• Tuberculosis — subacute course, upper lobe predominance, exposure history
• PJP (Pneumocystis) — in severely immunocompromised; bilateral GGOs, elevated LDH

Key distinguishing features for Legionella: Pneumonia + diarrhea + hyponatremia + elevated CK + failure to respond to β-lactams [3][5]

• Prior episodes of pneumonia and causative organisms
• Transplant history and immunosuppressive regimen
• Chronic lung disease, heart failure
• Recent hospitalizations (nosocomial Legionella)
• Steroid use (associated with cavitary disease) [9]

• Vitals: High fever (often >38.8°C), relative bradycardia (pulse-temperature dissociation — classically described though nonspecific), tachypnea, hypoxia [3][10]
• Lungs: Crackles, bronchial breath sounds, signs of consolidation; may be unilateral early, progressing to bilateral
• Neuro: Assess for confusion, obtundation, focal deficits
• Abdomen: Diffuse tenderness possible with prominent GI involvement
• Skin: No characteristic rash (helps distinguish from other atypical infections)
• Volume status: Assess for dehydration from fever and diarrhea

• Legionella urinary antigen (UAT): First-line rapid test; sensitivity 56–99% but only detects L. pneumophila serogroup 1; positive within 48–72 hours of symptom onset [3]
• Legionella PCR (respiratory specimens): Superior sensitivity (97%) and detects all serogroups/species; should be used for early diagnosis [2][11]
• Respiratory culture on BCYE agar: Gold standard but slow (3–5 days) [2]
• Characteristic lab abnormalities: [3][10]
  • Hyponatremia (Na <130 mmol/L) — more frequent than in other pneumonias
  • Elevated CK / myoglobinuria (rhabdomyolysis)
  • Hypophosphatemia
  • Elevated ferritin (often >2× normal)
  • Leukocytosis with relative lymphopenia
  • Elevated ESR, CRP
  • Microscopic hematuria
  • Elevated LFTs
• Standard workup: CBC, BMP (Na, BUN/Cr), LFTs, CK, lactate, procalcitonin, blood cultures, sputum Gram stain/culture

• Chest X-ray (first-line): Patchy unilobar infiltrate progressing to consolidation; lower lobes most commonly involved; no pathognomonic pattern [3][12]
• Pleural effusion: Present in 15–50% at admission; additional effusions commonly develop during the first week even with appropriate therapy [3][13]
• Radiographic worsening: >50% of patients show progression of infiltrates within the first week despite appropriate antibiotics — this is expected and should not prompt premature antibiotic changes [13]
• CT chest: Consolidation (94%), ground-glass opacities, halo sign (26% in oncologic patients); cavitation in ~10% of immunosuppressed patients [14-15]
• Key pearl: Imaging cannot distinguish Legionella from other bacterial pneumonias; it is useful for monitoring progression, not diagnosis [13]

• Legionella urinary antigen test — rapid (15 minutes), widely available; remains positive for weeks [3]
• Respiratory multiplex PCR panels — many now include L. pneumophila [16]
• Serology (antibody titers): Not useful acutely — seroconversion takes ≥3 weeks and never occurs in ~25% of culture-proven cases [3]
• Severity scoring: Use PSI (preferred) or CURB-65 to guide disposition [17-18]

• ECG is not routinely diagnostic but should be obtained in patients with chest pain, hemodynamic instability, or suspected cardiac involvement
• Relative bradycardia (pulse-temperature dissociation) is a classic but nonspecific finding [3][10]
• Rare cardiac complications: myocarditis (new gallop, heart failure, ECG changes including ST-T wave abnormalities), pericarditis, sinoatrial block [19-20]
• Pneumonia in general can cause nonspecific ST-T changes, right-axis deviation, and S1Q3T3 pattern mimicking PE [21]

• Legionnaires' disease presents as a spectrum from mild pneumonia to fulminant multiorgan failure
• The classic clinical profile — high fever, relative bradycardia, diarrhea, confusion, hyponatremia, elevated CK, failure to improve on β-lactams — should prompt immediate testing and empiric coverage [5][10]
• No single clinical or radiographic feature is pathognomonic [2]
• Complications: Respiratory failure, rhabdomyolysis, acute renal failure, CNS involvement (encephalopathy, seizures), myocarditis, empyema [2][4]
• Recovery is often slow — fatigue, neuromuscular symptoms, and even PTSD have been reported post-recovery [3]

Initial stabilization

• Supplemental O₂ to maintain SpO₂ ≥94%; early intubation if progressive respiratory failure
• IV fluid resuscitation (especially with diarrhea and high fevers)
• Vasopressors if septic shock

Antibiotic therapy

• Mild/outpatient: Oral azithromycin 500 mg daily × 3–5 days OR levofloxacin 750 mg daily × 5 days OR doxycycline 100 mg BID [3]
• Moderate-severe/inpatient: IV azithromycin 500 mg daily or IV levofloxacin 750 mg daily; transition to oral when clinically improving [2-3]
• Immunocompromised: Extend duration to 10 days (azithromycin) or 14–21 days (levofloxacin/other agents) [2-3]
• Do not stop antibiotics until afebrile for 48–72 hours [2]
• No evidence supports dual antibiotic therapy [2][6]

Supportive care

• Monitor for rhabdomyolysis (aggressive IV hydration, serial CK)
• Correct electrolyte abnormalities (hyponatremia, hypophosphatemia)
• Renal replacement therapy if indicated

• Admission criteria: Hypoxia, hemodynamic instability, inability to tolerate oral medications, significant comorbidities, CURB-65 ≥2 or PSI class IV–V, multiorgan involvement [17-18]
• ICU admission: Mechanical ventilation, vasopressor requirement, rapidly progressive infiltrates, multiorgan failure — nearly one-third of Legionella pneumonia cases require ICU care [1]
• Discharge criteria: Afebrile ≥48 hours, tolerating oral antibiotics, stable/improving oxygenation, no evidence of complications
• Observation: Consider for patients with CURB-65 score of 2 or borderline severity
• Mandatory public health notification: Report confirmed cases immediately to local/state health authorities for source investigation [2]

• Follow-up: PCP or pulmonology within 1–2 weeks of discharge; repeat CXR at 6–8 weeks to confirm radiographic resolution (especially in smokers and patients >50 to exclude underlying malignancy)
• Expected course: Clinical improvement typically within 3–5 days of appropriate antibiotics; radiographic clearing may lag behind clinical improvement by weeks [13]
• Return precautions — instruct patients to return immediately for:
  • Worsening dyspnea or new oxygen requirement
  • Recurrent high fevers after initial improvement
  • Confusion or altered mental status
  • Dark urine or decreased urine output
  • Persistent vomiting/inability to take oral medications
• Patient counseling: Recovery can be prolonged — fatigue, weakness, and cognitive symptoms may persist for weeks to months [3]
• No person-to-person transmission; household contacts do not require prophylaxis

1. Severe Legionnaires' Disease. — Rello J, Allam C, Ruiz-Spinelli A, Jarraud S. Annals of Intensive Care. 2024.

2. Epidemiology and Clinical Management of Legionnaires' Disease. — Phin N, Parry-Ford F, Harrison T, et al. The Lancet. Infectious Diseases. 2014.

3. Legionnaires' Disease. — Cunha BA, Burillo A, Bouza E. Lancet. 2016.

4. Legionellosis. — Stout JE, Yu VL. The New England Journal of Medicine. 1997.

5. Comparative Study of the Clinical Presentation of Legionella Pneumonia and Other Community-Acquired Pneumonias. — Sopena N, Sabrià-Leal M, Pedro-Botet ML, et al. Chest. 1998.

6. Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-Analysis. — Jasper AS, Musuuza JS, Tischendorf JS, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2021.

7. Risk Factors, Management, and Outcomes of Legionella Pneumonia in a Large, Nationally Representative Sample. — Allgaier J, Lagu T, Haessler S, et al. Chest. 2021.

8. A Case-Control Study on Chlamydia Psittaci Pneumonia and Legionella Pneumonia. — Gao Y, Lin YJ, Zhang WL, et al. Frontiers in Medicine. 2025.

9. Chest Computed Tomographic Findings and Clinical Features of Legionella Pneumonia. — Kim KW, Goo JM, Lee HJ, et al. Journal of Computer Assisted Tomography. 2007.

10. Clinical Aspects of Legionnaires' Disease. — Swartz MN. Annals of Internal Medicine. 1979.

11. Diagnostic Accuracy of PCR Alone and Compared to Urinary Antigen Testing for Detection of Legionella Spp.: A Systematic Review. — Avni T, Bieber A, Green H, et al. Journal of Clinical Microbiology. 2016.

12. The Chest Roentgenogram in Sporadic Cases of Legionnaires' Disease. — Storch GA, Sagel SS, Baine WB. The Journal of the American Medical Association. 1981.

13. The Radiologic Manifestations of Legionnaire's Disease. The Ohio Community-Based Pneumonia Incidence Study Group. — Tan MJ, Tan JS, Hamor RH, File TM, Breiman RF. Chest. 2000.

14. Pulmonary Legionellosis in Oncologic Patients: Findings on Chest CT. — Shroff GS, Marom EM, Wu CC, et al. Journal of Computer Assisted Tomography. 2016.

15. Computed Tomographic Features of 23 Sporadic Cases With Legionella Pneumophila Pneumonia. — Yu H, Higa F, Hibiya K, et al. European Journal of Radiology. 2010.

16. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

17. Community-Acquired Pneumonia. — File TM, Ramirez JA. The New England Journal of Medicine. 2023.

18. Diagnosis and Treatment of Adults With Community-Acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. — Metlay JP, Waterer GW, Long AC, et al. American Journal of Respiratory and Critical Care Medicine. 2019.

19. Myocarditis in Legionnaires' Disease. — Gross D, Willens H, Zeldis SM. Chest. 1981.

20. Sinoatrial Block Complicating Legionnaire's Disease. — Medarov B, Tongia S, Rossoff L. Postgraduate Medical Journal. 2003.

21. Electrocardiogram in Pneumonia. — Stein PD, Matta F, Ekkah M, et al. The American Journal of Cardiology. 2012.